Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pliant Therapeutics ( (PLRX) ) has provided an announcement.
On October 14, 2025, Pliant Therapeutics, Inc. completed a voluntary prepayment of $32.4 million, settling all outstanding obligations under its Loan Agreement with Oxford Finance LLC. This move effectively discharged all debts and terminated the Loan Agreement, which initially allowed for term loans up to $150 million, of which $30 million was borrowed.
The most recent analyst rating on (PLRX) stock is a Hold with a $1.70 price target. To see the full list of analyst forecasts on Pliant Therapeutics stock, see the PLRX Stock Forecast page.
Spark’s Take on PLRX Stock
According to Spark, TipRanks’ AI Analyst, PLRX is a Underperform.
Pliant Therapeutics is currently facing substantial financial difficulties, with zero revenue in 2024 and ongoing net losses. These challenges are reflected in the low financial performance score. Technical analysis shows bearish trends but hints at a potential short-term rebound. Valuation remains poor due to a negative P/E ratio and lack of dividends. Additionally, a significant workforce reduction indicates further strategic challenges. Overall, these factors contribute to a low stock score, indicating high risk and limited appeal for potential investors.
To see Spark’s full report on PLRX stock, click here.
More about Pliant Therapeutics
Pliant Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapies for fibrotic diseases. The company is involved in creating innovative treatments targeting fibrosis across various organs.
Average Trading Volume: 819,129
Technical Sentiment Signal: Sell
Current Market Cap: $96.38M
Find detailed analytics on PLRX stock on TipRanks’ Stock Analysis page.